FDA Grants Tentative Approval to Merck’s Insulin Glargine Copycat

Drug Industry Daily
A A
The FDA granted tentative approval for Merck’s Lusduna Nexvue (insulin glargine injection), as a follow-on basal insulin biologic, a product similar to Sanofi’s flagship Lantus treatment.

To View This Article:

Login

Subscribe To Drug Industry Daily